Arcutis Biotherapeutics to Host Virtual Investor Day and Report Third Quarter 2025 Financial Results on October 28, 2025

Core Viewpoint - Arcutis Biotherapeutics, Inc. will report its third quarter 2025 financial results on October 28, 2025, and will host a virtual Investor Day to discuss these results and other strategic initiatives [1][2]. Company Overview - Arcutis Biotherapeutics is a commercial-stage medical dermatology company focused on innovative solutions for immune-mediated dermatological diseases, with a portfolio of advanced targeted topicals approved for three major inflammatory skin diseases [3]. - The company utilizes a unique dermatology development platform and expertise to create differentiated therapies targeting biologically validated conditions, resulting in a robust pipeline for various inflammatory dermatological issues [3]. Upcoming Events - The Investor Day will include presentations from the management team and a fireside chat with Douglas DiRuggiero, PA-C, DMSc, highlighting the company's strategy and clinical advancements [1][5]. - A Q&A session will follow the formal presentations, and a live webcast will be available on the company's website, with an archived replay posted afterward [2]. Strategic Focus - The event will provide an in-depth look into the company's long-term growth strategy for ZORYVE® (roflumilast), clinical development activities for new indications, and an overview of the capital allocation strategy and financial outlook [5].